Patents are legal documents drawn up by inventors and lawyers and granted by various patent offices around the world, to protect the inventors' intellectual property. The short description accompanying each patent in this Patents section is therefore taken from the legal document as is, with minor corrections for Greek symbols and obvious spelling errors. The patents included in this section may be for material products (defensins or defensin-like peptides or nucleic acid sequences, synthetic or natural) or for novel methods of detecting, quantitating, synthesizing, or delivering antimicrobial peptides/nucleic acid sequences in general. The curators' criterion for inclusion in this section is broader for novel methods than for material products, in the hope that these methods may in future be similarly applied to defensins.

Patents in which the defensins or defensin-like material products and methods as above are not novel, such as biomarker sets containing unmodified defensin or defensin-like peptides or oligonucleotides, are excluded from this section. The exception to such exclusions is where the patent provides other novel defensin-related material products or methods in addition to those non-novel of the biomarker set itself. This exclusion is because the reasonable presence of defensin or defensin-like sequences or indeed any other sequences in patented biomarker sets is necessarily attributed to some prior discovery of disease state correlation with such sequences. The curators have observed therefore that the novel discovery in biomarker-related patents is often the method of biomarker array analysis and validation as well as its resultant implications for diagnostics and prognostics. The expert evaluation of such biomarker analysis and validation is well outside the scope of the Defensins Knowledgebase. The reader is respectfully referred to a biomarker database specific to the disease to perform his own assessment of the validity of the biomarker.

Methods not pertaining to the antimicrobial activity of defensins, but where defensins or antimicrobial peptides or small cationic peptides or disulphide-bonded peptides or their respective nucleic acid sequences are suggested in some unambiguous detail to play a useful role in the method, with or without supporting experimental evidence, are included as well in this section. Patents in which natural defensins are up/downregulated in a clearly defined signal transduction pathway as a result of the unrelated patented novel compound or method are also included. And lastly, all patents showing experimental work done with defensins or antimicrobial peptides or small cationic peptides or disulphide-bonded peptides or their respective nucleic acid sequences, where such peptides or nucleic acid sequences are not the experimental controls, are included without exception.

The data in this section have been extracted from the academic version of SciFinder Scholar 2007 and from public Google search - a wide range of defensin-related patents are included.


Results 231 - 240 of 333

<< Previous | 15 | 16 | 17 | 18 | 19 | 20 | 21 | 22 | 23 | 24 | 25 | 26 | 27 | 28 | 29 | 30 | 31 | 32 | 33 | 34 | Next >>

Last updated: 20th February 2008

Patent No.: US 6077680
ShK toxin compositions and methods of use.
Applicant: Kem WR, Pennington M, Norton RS, Chandy KG, Kalman K (2000)
Disclosed are methods and compositions comprising DNA segments, and proteins derived from sea anemone species. More particularly, it concerns the novel ShK toxin, ShK toxin analogs, chemically-modified toxin analogs, and nucleic acid segments encoding the ShK toxin from Stichodactyla helianthus. Various methods for making and using these DNA segments, DNA segments encoding synthetically-modified ShK toxins, and native and synthetic ShK peptides are disclosed, such as, for example, the use of DNA segments as diagnostic probes and templates for protein production, and the use of proteins, fusion protein carriers and peptides in various immunological and diagnostic applications.

Patent No.: US 6072041
Fusion proteins for protein delivery.
Applicant: Davis PB, Ferkol T, Eckman E, Schreiber J, Luk JM (2000)
A protein conjugate consisting of antibody directed at the pIgR and A.sub.1 AT can be transported specifically from the basolateral surface of epithelial cells to the apical surface. This approach provides us with the ability to deliver a therapeutic protein directly to the apical surface of the epithelium, by targeting the pIgR with an appropriate ligand. Thus, the highest concentration of the antiprotease will be at the apical surface, where it can do the greatest good in accelerating the inflammatory response.

Patent No.: US 6071879
Method for the treatment of bacterial infection.
Applicant: Pereira HA (2000)
The present invention contemplates a composition and method for treating a bacterial infection in a mammal. Comprising/administering a therapeutically effective amount of a peptide derived from CAP37 protein. In a preferred version, the composition and method of use may comprise a peptide comprising amino acids 20-44 or 120-146 of CAP37 or subunits thereof.

Patent No.: US 6057291
Antimicrobial cationic peptides.
Applicant: Hancock REW, Karunaratne N (2000)
A novel class of cationic peptides having antimicrobial activity is provided. Examples of such peptides include NH.sub.2 --KWKSFIKKLTTAVKKVLTTGLPALIS--COOH (SEQ ID NO:1) and NH.sub.2 --KWKSFIKKLTSAAKKVVTTAKPLISS--COOH (SEQ ID NO:2). Also provided are methods for inhibiting the growth of bacteria utilizing the peptides of the invention. The peptides are particularly useful for inhibiting endotoxemia in a subject.

Patent No.: US 6057142
Human chitinase, its recombinant production, its use for decomposing chitin, its use in therapy or prophylaxis against infection diseases.
Applicant: Aerts JMFG (2000)
A new human chitinase having an amino acid sequence as shown in FIG. 1 or FIG. 2. Modified forms of it having a similar chitin-hydrolyzing activity, and antigenic peptides representing one of its epitopes. Recombinant production of the human chitinase by genetically engineered hosts or host cells. Recombinant nucleic acid encoding it, and human chitinase-specific oligonucleotides. Use for therapeutic or prophylactic treatment of humans against infection by chitin-containing pathogens, or for decomposing chitin, e.g. from chitin-based articles. Antibodies binding to the human chitinase. Diagnostic test kits comprising the human chitinase, its antigenic peptides, human chitinase antibodies, recombinant nucleic acid or oligonucleotides.

Patent No.: US 6054133
Anti-microbial targeting for intracellular pathogens.
Applicant: Horwitz MA, Clemens DL (2000)
A method and composition are provided for treating intracellular pathogens that reside in phagosomes. The compositions include antibiotics which are conjugated with transferrin or other ligands to form conjugates that target membrane-bound pathogens. The conjugates are selectively taken up by infected phagosomes. Conjugates are provided which utilize transferrin as the targeting ligand for treating mycobacterium which reside in membrane-bound phagosomes.

Patent No.: US 6043220
Threonine-containing protegrins.
Applicant: Chang CC, Chen J, Lehrer RI, Radel PA (2000)
The invention is directed to antimicrobial peptides related to naturally-occurring protegrin peptides, and methods of using the peptides in a variety of contexts, including the treatment or prevention of infections, and diseases related thereto.

Patent No.: US 6043218
Positively charged non-natural amino acids, methods of making thereof, and use thereof in peptides.
Applicant: Dix TA (2000)
This invention relates to positively charged non-natural amino acids, methods of making thereof, and utilization thereof in peptides. In one embodiment, the invention relates to non-natural amino acids that closely replicate the natural amino acids lysine and arginine.

Patent No.: US 6042848
Enhancement of antimicrobial peptide activity by metal ions.
Applicant: Lawyer CH, Watabe K (2000)
Provided are methods for maintaining or enhancing the antimicrobial activity of antimicrobial peptides, lytic peptides, and peptide-derived antibiotics by the use of metal ions. Also provided are pharmaceutical and other compositions comprising such peptides and/or at least one metal ion. Also provided are therapeutic and other methods for controlling the growth of undesirable or pathogenic microorganisms in various loci or milieu in, on, or outside the body employing these peptides and metal ions. Also provided are kits comprising containers containing a peptide and a metal ion(s), respectively.

Patent No.: US 6037456
Process for isolating and purifying viruses, soluble proteins and peptides from plant sources.
Applicant: Garger SJ, Holtz RB, McCulloch MJ, Turpen TH (2000)
The present invention features a method for isolating and purifying viruses, proteins and peptides of interest from a plant host which is applicable on a large scale. Moreover, the present invention provides a more efficient method for isolating viruses, proteins and peptides of interest than those methods described in the prior art. In general, the present method of isolating viruses, proteins and peptides of interest comprises the steps of homogenizing a plant to produce a green juice, adjusting the pH of and heating the green juice, separating the target species, either virus or protein/peptide, from other components of the green juice by one or more cycles of centrifugation, resuspenion, and ultrafiltration, and finally purifying virus particles by such procedure as PEG-precipitation or purifying proteins and peptides by such procedures as chromatography and/or salt precipitation.